Avacta Submits Clinical Trial Application for AVA6000 pro-doxorubixin

Avacta Submits Clinical Trial Application for AVA6000 pro-doxorubixin
FAP-activated Doxorubicin prodrug
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that it has submitted a Clinical Trial Application (CTA) in the UK for a Phase 1, first-in-human, open label, dose-escalation and expansion study of its lead pre|CISION prodrug, AVA6000, in patients with locally advanced or metastatic selected solid tumours.
In AVA6000, Doxorubicin has been modified with Avacta's pre|CISION chemistry which renders the modified drug inactive in the circulation until it enters the tumour micro-environment where it is activated by an enzyme called FAP (fibroblast activation protein) which is in high abundance in most solid tumours but not in healthy tissue such as the heart. AVA6000 has been shown in animal models to significantly increase the amount of active drug in a tumour compared with the heart and should thereby improve tolerability and achieve better clinical outcomes for patients.

Related Keywords

United Kingdom , Katie Odgaard , Alastair Smith , Oneil Bell , Avacta Group , Zyme Communications , Tufts University , Regulatory Agency , Clinical Trial Application , Chief Executive Officer , Chief Development Officer , ஒன்றுபட்டது கிஂக்டம் , அலெஸ்டர் ஸ்மித் , நீல் மணி , ஜய்மே தகவல்தொடர்புகள் , டஃப்ட்ஸ் பல்கலைக்கழகம் , மருத்துவ சோதனை விண்ணப்பம் , தலைமை நிர்வாகி அதிகாரி , தலைமை வளர்ச்சி அதிகாரி ,